---
document_datetime: 2023-09-21 17:54:37
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/ganfort-epar-procedural-steps-taken-authorisation_en.pdf
document_name: ganfort-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.6258644
conversion_datetime: 2025-12-30 11:28:59.959655
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## 1 BACKGROUND INFORMATION ON THE PROCEDURE

## 1.1 Submission of the dossier

The  applicant  Allergan  Pharmaceuticals  Ireland    submitted  on  26  April  2005  an  application  for Marketing  Authorisation  to  the  European  Medicines  Agency  (EMEA)  for  Ganfort,  through  the centralised procedure.

## The legal basis for this application refers to:

Article 8.3 of Directive 2001/83/EC, as amended - complete and independent application.

## Scientific Advice:

The applicant did not seek scientific advice at the CHMP.

## Licensing status:

The product was not licensed in any country at the time of submission of the application.

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur Dr. S. Thirstrup

Co-Rapporteur Dr. G. Calvo Rojas

## 1.2 Steps taken for the assessment of the product

- The application was received by the EMEA on 26 April 2005.
- The  Rapporteur's  first  Assessment  Report  was  circulated  to  all  CHMP  members  on  27  July 2005. The Co-Rapporteur's first Assessment Report was circulated to all CHMP members on 04 August 2005.
- The procedure started on 18 May 2005.
- During the meeting on 12-15 September 2005, the CHMP agreed on the consolidated List of Questions to be sent to the applicant. The final consolidated List of Questions was sent to the applicant on 16 September 2005.
- The  applicant  submitted  the  responses  to  the  CHMP  consolidated  List  of  Questions  on  16 December 2005.
- The Rapporteurs circulated the Joint Assessment Report on the applicant's responses to the List of Questions to all CHMP members on  24 January 2006.
- During the CHMP meeting on 20-23 February 2006, the CHMP agreed on a list of outstanding issues to be addressed in writing and by the applicant.
- The  applicant  submitted  written  explanations  to  the  CHMP  consolidated  List  of  Outstanding Issues on 1 March 2006.
- The Rapporteurs circulated the Joint Assessment Report on the applicant's responses to the List of Outstanding Issues to all CHMP members on 08 March 2006.
- During the meeting on 20-23 March 2006, the CHMP, in the light of the overall data submitted and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a Marketing  Authorisation  to  Ganfort  on  23  March  2006.  The  applicant  provided  the  letter  of undertaking on the follow-up measures to be fulfilled post-authorisation on 14 March 2006. The European Commission granted a marketing authorisation valid throughout the European Union for Ganfort on 19 May 2006.